Moreover, from a clinical perspective, targeting the NBR1-p62-Nrf2 pathway could potentially lead to the development of innovative therapeutic strategies for managing pulmonary fibrosis, addressing a critical medical need. This evidence concerns the gene NFE2L2 and pulmonary fibrosis.